Page last updated: 2024-10-25

ciglitazone and Melanoma

ciglitazone has been researched along with Melanoma in 7 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research Excerpts

ExcerptRelevanceReference
"We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, independently of PPARγ activation, melanoma cell growth."7.77Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. ( Ballotti, R; Bertolotto, C; Botton, T; Cheli, Y; Deckert, M; Fajas, L; Giuliano, S; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Tomic, T, 2011)
" In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone."7.75In vitro and in vivo anti-melanoma effects of ciglitazone. ( Annicotte, JS; Bahadoran, P; Ballotti, R; Bertolotto, C; Botton, T; Fajas, L; Gozzerino, G; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Zamoum, T, 2009)
"We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, independently of PPARγ activation, melanoma cell growth."3.77Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. ( Ballotti, R; Bertolotto, C; Botton, T; Cheli, Y; Deckert, M; Fajas, L; Giuliano, S; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Tomic, T, 2011)
" In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone."3.75In vitro and in vivo anti-melanoma effects of ciglitazone. ( Annicotte, JS; Bahadoran, P; Ballotti, R; Bertolotto, C; Botton, T; Fajas, L; Gozzerino, G; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Zamoum, T, 2009)
"The PPAR-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone, and the PPAR-alpha ligand, WY-14643, were examined for their effects on proliferation and apoptosis of A375 melanoma, DU145 and PC3 prostate cancer, and MB-MDA-231 breast cancer."3.73PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. ( Liu, H; Meadows, GG; Núñez, NP, 2006)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Botton, T2
Puissant, A2
Bahadoran, P1
Annicotte, JS1
Fajas, L2
Ortonne, JP2
Gozzerino, G1
Zamoum, T1
Tartare-Deckert, S2
Bertolotto, C2
Ballotti, R2
Rocchi, S2
Schadendorf, D1
Cheli, Y1
Tomic, T1
Giuliano, S1
Deckert, M1
Paulitschke, V1
Gruber, S1
Hofstätter, E1
Haudek-Prinz, V1
Klepeisz, P1
Schicher, N1
Jonak, C1
Petzelbauer, P1
Pehamberger, H1
Gerner, C1
Kunstfeld, R1
Placha, W2
Gil, D1
Dembińska-Kieć, A1
Laidler, P2
Núñez, NP1
Liu, H1
Meadows, GG1
Grabacka, M1
Urbanska, K1
Płonka, PM1
Reiss, K1

Other Studies

7 other studies available for ciglitazone and Melanoma

ArticleYear
In vitro and in vivo anti-melanoma effects of ciglitazone.
    The Journal of investigative dermatology, 2009, Volume: 129, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Re

2009
Peroxisome proliferator-activating receptors: a new way to treat melanoma?
    The Journal of investigative dermatology, 2009, Volume: 129, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Humans; Melanoma; PPAR gamma; Signal Transduction; Skin Neoplasms;

2009
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.
    Cell death and differentiation, 2011, Volume: 18, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Chemokine CXCL1;

2011
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromans; Hu

2012
The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells.
    Melanoma research, 2003, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; DNA; Dose-Resp

2003
PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.
    Cancer letters, 2006, May-08, Volume: 236, Issue:1

    Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio

2006
PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
    Pigment cell & melanoma research, 2008, Volume: 21, Issue:3

    Topics: Alitretinoin; Animals; Antigens, Differentiation; Antineoplastic Agents; beta Catenin; Blotting, Wes

2008